GSGuoli Sun

Guoli Sun

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Guoli Sun has a total of 71 co-authors. Here are the top co-authors by number of shared publications:

  • Yong Liu

    Department of Cardiology, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China

    7 shared publications
  • Adelina Yafasova

    Department of Cardiology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark

    5 shared publications
  • Mikkel Faurschou

    Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital , Copenhagen

    5 shared publications
  • Feier Song

    Department of Emergency and Critical Care Medicine, Guangdong Provincial People’s Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People’s Republic of China

    4 shared publications
  • Jawad Haider Butt

    British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom; Department of Cardiology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark

    4 shared publications
  • Ji-Yan Chen

    Department of Cardiology, Guangdong Provincial People's Hospital affiliated with South China University of Technology, Guangzhou, China

    3 shared publications

Latest Publications

  • Venous thromboembolism in 5-year cancer survivors: a nationwide cohort study

    by Adelina Yafasova, Guoli Sun, Martin Hutchings, Seiko N Doi, Morten Schou, Maja V Maraldo, Amna Alhakak, Nina Nouhravesh, John J V McMurray, Mark C Petrie, et al.

    Aims: Cancer is associated with a significant short-term risk of venous thromboembolism (VTE). With substantial improvements in cancer survival, concern has been raised about an increased risk of VTE in long-term cancer survivors. We aimed to investigate the long-term risk of VTE in 5-year cancer survivors according to cancer subtype, age, and sex compared with a matched background population. Methods and results: Using Danish nationwide registries, we matched 5-year survivors of 21 cancers (≥18 years; diagnosed 2000–2017; included 2005–2022 [5 years after cancer diagnosis]) with individuals from the background population (1:1 matching for the overall population and 1:4 matching for each cancer subtype). Rates of VTE were examined using Cox regression. In the overall population, 222 297 five-year cancer survivors were matched with 222 297 individuals from the background population (median age 69.2 years; 43.6% males). During a median follow-up of 5.6 years, cancer survivors had a higher associated rate of VTE compared with the background population (adjusted hazard ratio [aHR] 1.85 [95%CI, 1.78–1.93]). Survivors of all 21 cancer subtypes had a higher associated rate of VTE compared with the background population, with the highest incidence rates found for multiple myeloma. HRs were higher in younger cancer survivors compared with older cancer survivors (<50 years: aHR, 2.85 [95%CI, 2.33–3.47]; 50–64 years: aHR, 2.26 [95%CI, 2.07–2.46]; ≥65 years: aHR, 1.69 [95%CI, 1.61–1.77]; Pinteraction<0.0001). Similar HRs were found in females and males (females: aHR 1.84 [95%CI, 1.75–1.95]; males: aHR 1.86 [95%CI, 1.75–1.98]; Pinteraction=0.94). Conclusion: Five-year cancer survivors had a higher associated rate of VTE compared with the background population.

  • Long-Term Rate of Heart Failure in Patients with Autoimmune Disease: A Nationwide Cohort Study

    by Guoli Sun, Emil L. Fosbøl, Mikkel Faurschou, Morten Schou, Christian Torp-Pedersen, Lars Køber, Jawad H. Butt

    Aims: Although certain autoimmune diseases (AIDs) have been associated with an increased rate of heart failure (HF), data on the long-term rate of HF across the spectrum of AIDs are lacking. We investigated the long-term rate of HF in individuals with a history of 28 different AIDs. Methods and results: Individuals diagnosed with an AID (2000–2021) were identified through Danish nationwide registries. Each patient with AID was matched with four individuals from the background population by age, sex, and year of inclusion. Multivariable Cox regression was used to compare the rate of HF between the AID and the background population, overall and according to individual AIDs. In total, 272 959 patients diagnosed with AID were matched with 1 091 836 individuals without AID (median age 55 years; 62% women; median follow-up 7.9 years). The 10-year cumulative incidence of HF was 5.2% for patients with AID and 3.5% for matched individuals. Patients with any AID had a higher associated rate of HF than matched individuals (hazard ratio [HR] 1.55, 95% confidence interval [CI] 1.52–1.59). Patients with each of the AIDs had a higher associated rate of incident HF compared with matched individuals from the background population, although the association was not statistically significant for Reiter's and Behcet's disease. The highest relative rates were observed in patients with systemic sclerosis (HR 3.31, 95% CI 2.63–4.16) and Addison's disease (HR 3.03, 95% CI 2.35–3.91). Conclusion: Patients with AID, irrespective of the type, had a higher associated rate of HF compared to the background population. Further research is needed to clarify whether screening for cardiovascular risk is beneficial.


  • Long-term rate of ventricular arrhythmia in autoimmune disease

    by Guoli Sun, Emil L Fosbøl, Morten Schou, Mikkel Faurschou, Adelina Yafasova, Jeppe K Petersen, Ketil J Haugan, Ulrik Madvig Mogensen, Jesper H Svendsen, Lars Køber, et al.

    Aims: Although selected autoimmune diseases (AIDs) have been linked to an increased risk of ventricular arrhythmias (VAs), data on the long-term rate of VAs across the spectrum of AIDs are lacking. The aim of this study was to investigate the long-term rate of VAs (a composite of ventricular tachycardia, ventricular fibrillation, ventricular flutter, or cardiac arrest) in individuals with a history of 28 different AIDs. Methods and results: Individuals diagnosed with an AID (2005–18) were identified through Danish nationwide registries. Each patient with an AID was matched with four individuals from the background population by age and sex. Multivariable Cox regression was used to compare the rate of VAs between the AIDs and background population, overall and according to individual AIDs. In total, 186 733 patients diagnosed with AIDs were matched with 746 932 individuals without AIDs (median age 55 years; 63% female; median follow-up 6.0 years). The 5-year cumulative incidence of VAs was 0.5% for patients with AIDs and 0.3% for matched individuals. Patients with any AIDs had a higher associated rate of VAs than matched individuals {hazard ratio (HR) 1.39 [95% confidence interval (CI), 1.29–1.49]}. The highest HR was observed in patients with systemic sclerosis [3.86 (95% CI, 1.92–7.75)]. The higher rate of VAs in patients with AIDs, compared with individuals from the background population, was more pronounced in patients without ischaemic heart disease or heart failure/cardiomyopathy compared with those with these conditions (Pinteraction <0.05). Conclusion: Despite a low cumulative incidence, patients with a history of AIDs had a higher relative rate of VAs than matched individuals.


  • Mortality in heart failure with and without autoimmune disease

    by Guoli Sun, Mikkel Faurschou, Naja E Vinding, Adelina Yafasova, Søren L Kristensen, Ole Ahlehoff, Morten Schou, Emil L Fosbøl, Lars Køber, Jawad H Butt

    Aims: Autoimmune diseases (AIDs) are associated with a higher risk of heart failure (HF). However, data on the prognosis of HF patients with a history of AID are limited. The aim was to investigate the rates of all-cause mortality and HF hospitalization in a large, nationwide cohort of patient with HF according to a history of 29 AIDs Methods and results: Using Danish nationwide registries, each HF patient (diagnosed 2000–18) with a history of AID was matched with four HF patients without AID by age, sex, and year of HF diagnosis. Rates of outcomes were compared by Cox regression models. The prevalence of AID in patients with HF was 10.7%. In total, 21 256 HF patients with a history of AID were matched with 85 024 HF patients without AID (median age 77 years; 58.9% female). During a median follow-up of 3.2 years, the incidence rates per 100 person-years for all-cause mortality were 17.1 (95% confidence interval, 16.9–17.4) and 14.4 (14.3–14.6) in patients with and without AID, respectively. The corresponding rates for HF hospitalization were 5.0 (4.9–5.1) and 5.2 (5.1–5.4), respectively. A history of AID was associated with higher rate of all-cause mortality [hazard ratio (HR) 1.14 (1.12–1.17)], but not HF hospitalization [HR 1.00 (0.96–1.04)] compared with no AID. Conclusions: In a nationwide cohort study, patients with HF and a history of AID had a higher associated rate of mortality than those without a history of AID.


  • Open Access

    Long‐term risk of heart failure and other adverse cardiovascular outcomes in primary Sjögren's syndrome

    by Guoli Sun, Emil L. Fosbøl, Adelina Yafasova, Mikkel Faurschou, Jesper Lindhardsen, Christian Torp‐Pedersen, Lars Køber, Jawad H. Butt

    Background: Data on long‐term cardiovascular outcomes in primary Sjögren's syndrome (PSS) are scarce.Objectives: We aim to investigate the long‐term rate of incident heart failure (HF) and other adverse cardiovascular endpoints in patients with PSS compared with the general population and to investigate mortality in individuals with incident HF with or without a history of PSS.Methods: Using Danish nationwide registries, PSS patients (diagnosed 1996–2018) without a history of other autoimmune diseases were each matched with four individuals from the general population by sex, age, and comorbidities. Multivariable Cox regression was used to estimate the rate of cardiovascular outcomes. In addition, the rate of death from any cause was compared between PSS patients with incident HF and four age‐ and sex‐matched HF patients without PSS.Results: In total, 5092 patients with newly diagnosed PSS were matched with 20,368 individuals from the general population (median age 57 years, 87.3% women, median follow‐up 7.4 years). The cumulative incidence of HF at 10 years was 4.0% for PSS patients and 2.8% for matched individuals. After adjustment, patients with PSS had a higher associated rate of incident HF (hazard ratios [HR] 1.42 [95% CI, 1.20–1.68]) and other cardiovascular outcomes, compared with the background population. PSS patients with incident HF had a similar rate of death from all‐cause mortality compared with HF patients without PSS (HR 0.94 [0.74–1.19]).Conclusions: Patients with PSS had a higher associated rate of incident HF and other cardiovascular outcomes compared with the general population. In individuals with incident HF, a history of PSS was not associated with increased mortality.


  • Long-term Risk of Heart Failure and Other Adverse Cardiovascular Outcomes in Granulomatosis With Polyangiitis: A Nationwide Cohort Study

    by Guoli Sun, Adelina Yafasova, Bo Baslund, Mikkel Faurschou, Morten Schou, Abdulrahman N. Shams-Eldin, Søren Lund Kristensen, Peter E. Weeke, Christian Torp-Pedersen, Emil L. Fosbøl, et al.

    Objective: To examine the long-term rates of heart failure (HF) and other adverse cardiovascular (CV) outcomes in a nationwide cohort of patients diagnosed with granulomatosis with polyangiitis (GPA) compared with the general population.Methods: Using Danish nationwide registries, patients with newly diagnosed GPA were identified and matched 1:4 by age, sex, and comorbidities with subjects from the general population. Outcomes were compared using Cox regression. Due to violation of the proportional hazard assumption, landmark analyses for the first year and from 1 year were performed.Results: Of the 1923 patients with GPA, 1781 patients (median age 59 yrs, 47.9% men) were matched with 7124 subjects from the general population. The median follow-up was 6.4 years. The absolute 10-year risk of HF was 6.8% (95% CI 5.5–8.2%) for patients with GPA and 5.9% (5.3–6.6%) for the general population. During the first year after diagnosis, GPA was associated with a significantly higher rate of HF (hazard ratio [HR] 3.60, 95% CI, 2.28–5.67) and other adverse outcomes, including atrial fibrillation/flutter (HR 6.50, 95% CI 4.43–9.55) and ischemic stroke (HR 3.24, 95% CI 1.92–5.48), compared with the general population. After the first year, GPA was not associated with higher rates of HF or other CV outcomes compared with the general population, except atrial fibrillation/flutter (HR 1.38, 95% CI 1.12-1.70).Conclusion: During the first year after diagnosis, the rates of HF and other CV outcomes were higher in patients with GPA compared with the general population. However, after the first year, the rates of HF and other CV outcomes, except atrial fibrillation/flutter, were similar to those in the general population.


  • Predictive Value of Hypoalbuminemia for Contrast-Associated Acute Kidney Injury: A Systematic Review and Meta-Analysis

    by Liwei Liu, Zhubin Lun, Bo Wang, Li Lei, Guoli Sun, Jin Liu, Zhaodong Guo, Yibo He, Feier Song, Bowen Liu, et al.

    Contrast-associated acute kidney injury (CA-AKI) is a major adverse complication of intravascular administration of contrast medium. Current studies have shown that hypoalbuminemia might be a novel risk factor of CA-AKI. This systematic review and meta-analysis was performed to evaluate the predictive value of hypoalbuminemia for CA-AKI. Relevant studies were identified in Ovid-Medline, PubMed, Embase, and Cochrane Library up to December 31, 2019. Two authors independently screened studies, consulting with a third author when necessary to resolve discrepancies. The pooled odds ratio (OR) was calculated to assess the association between hypoalbuminemia and CA-AKI using a random-effects model or fixed-effects model. Eight relevant studies involving a total of 18 687 patients met our inclusion criteria. The presence of hypoalbuminemia was associated with an increased risk of CA-AKI development (pooled OR: 2.59, 95% CI: 1.80-3.73). Hypoalbuminemia is independently associated with the occurrence of CA-AKI and may be a potentially modifiable factor for clinical intervention. This systematic review and meta-analysis was registered in PROSPERO (CRD42020168104).


  • Patient-level and system-level barriers associated with treatment delays for ST elevation myocardial infarction in China

    by Xuejun Yin, Yibo He, Jing Zhang, Feier Song, Jin Liu, Guoli Sun, Yan Liang, Jianfeng Ye, Yunzhao Hu, Mingcai Song, et al.

    Objective This study aims to understand the current ST elevated myocardial infarction (STEMI) treatment process in Guangdong Province and explore patient-level and system-level barriers associated with delay in STEMI treatment, so as to provide recommendations for improvement. Methods This is a qualitative study. Data were collected using semistructured, face-to-face individual interviews from April 2018 to January 2019. Participants included patients with STEMI, cardiologists and nurses from hospitals, emergency department doctors, primary healthcare providers, local health governors, and coordinators at the emergency medical system (EMS). An inductive thematic analysis was adopted to generate overarching themes and subthemes for potential causes of STEMI treatment delay. The WHO framework for people-centred integrated health services was used to frame recommendations for improving the health system. Results Thirty-two participants were interviewed. Patient-level barriers included poor knowledge in recognising STEMI symptoms and not calling EMS when symptoms occurred. Limited capacity of health professionals in hospitals below the tertiary level and lack of coordination between hospitals of different levels were identified as the main system-level barriers. Five recommendations were provided: (1) enhance public health education; (2) strengthen primary healthcare workforce; (3) increase EMS capacity; (4) establish an integrated care model; and (5) harness government’s responsibilities. Conclusions Barriers associated with delay in STEMI treatment were identified at both patient and system levels. The results of this study provide a useful evidence base for future intervention development to improve the quality of STEMI treatment and patient outcomes in China and other countries in a similar situation.


  • Open Access

    Rationale and design of the Web-basEd soCial media tecHnology to improvement in Adherence to dual anTiplatelet Therapy following Drug-Eluting Stent Implantation (WECHAT): protocol for a randomised controlled study

    by Guo-Li Sun, Li Lei, Liwei Liu, Jin Liu, Yibo He, Zhaodong Guo, Xiaohua Dai, Lihao He, Shi-Qun Chen, Yan Liang, et al.

    Background Dual antiplatelet therapy (DAPT) is frequently discontinued after drug-eluting stent (DES) implantation, which could increase the risk of major adverse cardiovascular events (MACEs). Few studies have attempted to improve DAPT adherence through web-based social media. Objective To explore the effect of social media on DAPT adherence following DES implantation. Methods/design The WeChat trial is a multicentre, single-blind, randomised study (1:1). It will recruit 760 patients with DES who require 12 months of DAPT. The control group will only receive usual care and general educational messages on medical knowledge. The intervention group will receive a personalised intervention, including interactive responses and medication and follow-up reminders beyond the general educational messages. The primary endpoint will be the discontinuation rate which is defined as the cessation of any dual antiplatelet drug owing to the participants’ discretion within 1 year of DES implantation. The secondary endpoints will include medication adherence and MACEs. Both groups will receive messages or reminders four times a week with follow-ups over 12 months. Ethics and dissemination Ethical approval was granted by Ethics Committee of Guangdong Provincial People’s Hospital (GDREC2018327H). Results will be disseminated via peer-reviewed publications and presentations at international conferences. Trial registration number NCT03732066


  • Open Access

    Proper hydration in contrast-induced nephropathy among patients with acute myocardial infarction and cardiac insufficiency

    by Guoli Sun, Jin Liu, Feier Song, Yibo He, Ming Ying, Jiyan Chen, Yong Liu

    Backgrounds The recommended strategy to prevent contrast-induced nephropathy (CIN) among acute myocardial infarction (AMI) patients is adequate hydration. However, it is still controversial whether adequate hydration should be used to prevent CIN in AMI patients with Killip class>I.Methods In this prospective, observational registry study, 407 acute myocardial infarction (AMI) patients with Killip class>I undergoing percutaneous coronary intervention (PCI) were analyzed. The recommended hydration rate is haved before or after the procedure(0.5 mL/kg/h for Killip class >I). The endpoint was CIN(an absolute increase in serum creatinine of ≥ 0.5 mg/dL or a relative increase of ≥ 25% within 48-72 hours).Patients were divided into 2 groups by approximate median hydration volumn(HV)750ml. Multivariable logistic regression analysis was carried out to clarify the independent predictors of CIN and worsening heart failure(WHF).Results The total incidence of CIN was 24.6% in this study. There was a significant association between hydration volume and CIN in two hydration groups(HV >750 mL vs. HV=750ml)may be associated with a higher risk of CIN and WHF.